1. Home
  2. VITL vs RZLT Comparison

VITL vs RZLT Comparison

Compare VITL & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

N/A

Current Price

$9.42

Market Cap

557.9M

ML Signal

N/A

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

N/A

Current Price

$4.85

Market Cap

471.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VITL
RZLT
Founded
2007
2010
Country
United States
United States
Employees
N/A
58
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.9M
471.0M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
VITL
RZLT
Price
$9.42
$4.85
Analyst Decision
Buy
Strong Buy
Analyst Count
10
11
Target Price
★ $13.22
$9.80
AVG Volume (30 Days)
★ 1.8M
1.7M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
★ 23.47
EPS
N/A
★ N/A
Revenue
★ $759,444,000.00
N/A
Revenue This Year
$1.33
N/A
Revenue Next Year
$7.03
$2,481.32
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 25.26
N/A
52 Week Low
$7.95
$1.07
52 Week High
$43.80
$11.46

Technical Indicators

Market Signals
Indicator
VITL
RZLT
Relative Strength Index (RSI) 41.21 66.61
Support Level $8.73 $4.36
Resistance Level $13.71 $5.43
Average True Range (ATR) 0.53 0.31
MACD -0.03 0.11
Stochastic Oscillator 17.69 93.48

Price Performance

Historical Comparison
VITL
RZLT

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Share on Social Networks: